Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVast Res Share News (VAST)

Share Price Information for Vast Res (VAST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.22
Bid: 0.21
Ask: 0.23
Change: 0.005 (2.33%)
Spread: 0.02 (9.524%)
Open: 0.215
High: 0.22
Low: 0.215
Prev. Close: 0.215
VAST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Hutchmed sinks on US FDA drug rejection

Tue, 03rd May 2022 11:29

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

----------

AIM - WINNERS

----------

Vast Resources PLC, up 50% at 0.51 pence, 12-month range 0.08p-10.00p. The Romania and Zimbabwe-focused miner says revenue more than doubled to USD2.3 million in the first quarter from USD970,465 in the fourth quarter. Reports increase in tons milled and in dry-metric-ton production at the Baita Plai polymetallic mine in Romania.

----------

Eneraqua Technologies PLC, up 10% at 280.00p, up 1.1% from November listing price of 277.00p. The energy and water efficiency services provider wins contract from the Indian state government of Uttarakhand to reduce carbon emissions and improve water efficiency. The northern state has a population of over 10 million people. Contract is worth GBP900,000 from the state's Department of Horticulture will see Eneraqua supply systems to 340 horticultural farms across the state.

----------

AIM - LOSERS

----------

Hutchmed (China) Ltd, down 15% at 208.00p, 12-month range 202.50p-656.00p. The US Food & Drug Administration has rejected the drugmaker's surufatinib for treatment of pancreatic neuroendocrine tumours. In a complete response letter, the FDA said the current data package, based on two positive phase three trials in China and one bridging study in the US, does not support an approval in the US "at this time". The FDA said a multi-regional clinical trial of surufatinib required for US approval. Surufatinib was approved in China for the treatment of pNETs and extra-pancreatic neuroendocrine tumours in June 2021 and December 2020, respectively.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
16 May 2022 12:40

Vast Resources shares surge as it repays outstanding debt to Atlas

(Alliance News) Vast Resources PLC on Monday said it repaid all its outstanding bond debt to Atlas Special Opportunities LLC.

Read more
13 May 2022 11:15

IN BRIEF: Vast Resources issues 150 million shares for bond conversion

Vast Resources PLC - London-based miner with projects in Romania and Zimbabwe - Issues 151.3 million new ordinary shares at 0.27 pence each, compared to Thursday closing price of 1.37p. Vast now has 760.5 million shares in issue, so the issuance represents 20% of the enlarged total. The share issuance is in response to London-based Atlas Special Opportunities LLC choosing to convert bonds of USD500,000 nominal value. On May 3, Atlas had given Vast a non legally binding verbal assurance that it would do no more conversions.

Read more
3 May 2022 11:40

Vast Resources soars on jump in quarterly revenue and higher output

(Alliance News) - Vast Resources PLC's shares surged on Tuesday after the firm reported that revenue more than tripled in its first quarter on a contribution from Tajikistan and higher production.

Read more
12 Apr 2022 11:56

Vast raises £0.42m to increase mining volumes at Baita Plai

(Sharecast News) - Vast Resources announced the raising of £0.42m on Tuesday, to support its planned increase in mining volumes at the Baita Plai Polymetallic Mine.

Read more
31 Mar 2022 21:07

TRADING UPDATES: SSE's Transmission raises cash; Croda gets UK grant

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
7 Feb 2022 15:54

IN BRIEF: Vast Resources pulls out of deal for Gem Diamonds Botswana

IN BRIEF: Vast Resources pulls out of deal for Gem Diamonds Botswana

Read more
1 Feb 2022 22:07

TRADING UPDATES: BP signs biofuel deal; Elixirr expects revenue beat

TRADING UPDATES: BP signs biofuel deal; Elixirr expects revenue beat

Read more
1 Feb 2022 14:42

Vast Resources pulls out of Ghaghoo venture with Botswana Diamonds

(Sharecast News) - Mining company Vast Resources pulled out of its joint venture acquisition of Gem Diamonds Botswana (GDB) on Tuesday.

Read more
7 Dec 2021 12:05

Vast Resources appoints Andrew Hall to board as commercial director

(Sharecast News) - Vast Resources announced the formal appointment of Andrew Hall to the board as commercial director on Tuesday, with immediate effect.

Read more
10 Nov 2021 12:00

Vast completes latest sale of concentrate from Baita Plai

(Sharecast News) - Mining company Vast Resources updated the market on its producing Baita Plai polymetallic mine in Romania on Wednesday.

Read more
29 Oct 2021 21:48

IN BRIEF: Vast Resources narrows annual loss; raises cash

IN BRIEF: Vast Resources narrows annual loss; raises cash

Read more
28 Oct 2021 11:50

Vast Resources raises £1.35m to cover working capital shortfall

(Sharecast News) - Mining company Vast Resources has raised gross proceeds £1.35m gross through a placing, it announced on Thursday, to cover a shortfall in working capital.

Read more
28 Oct 2021 11:42

AIM WINNERS & LOSERS: Vast Resources falls after discounted placing

AIM WINNERS & LOSERS: Vast Resources falls after discounted placing

Read more
25 Oct 2021 17:53

TRADING UPDATES: Ridgecrest ends Blue Air deal; Vast's Baita Plai hit

TRADING UPDATES: Ridgecrest ends Blue Air deal; Vast's Baita Plai hit

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.